Manufacturer Supply; High Quality and Competitive Price
Commercial Supply Ezetimibe (CAS: 163222-33-1) Related Intermediates:
(S)-(+)-4-Phenyl-2-oxazolidinone CAS: 99395-88-7
(R)-(+)-2-Methyl-CBS-oxazaborolidine CAS: 112022-83-0
4-(4-Fluorobenzoyl)butyric acid CAS: 149437-76-3
4-[[(4-Fluorophenyl)imino]methyl]-phenol CAS: 3382-63-6
N-(4-(Benzyloxy)benzylidene)-4-fluoroaniline CAS: 70627-52-0
(3R,4S)-4-[4-(Benzyloxy)phenyl]-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one CAS: 190595-65-4
(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone CAS: 189028-93-1
(4S)-3-[(5S)-5-(4-Fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one CAS: 189028-95-3
Ezetimibe CAS: 163222-33-1
| Chemical Name | 4-[[(4-Fluorophenyl)imino]methyl]-phenol |
| CAS Number | 3382-63-6 |
| CAT Number | RF-PI145 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C13H10FNO |
| Molecular Weight | 215.22 |
| Melting Point | 179.0 to 183.0℃ |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | Off-White to White Powder |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Single Impurity | ≤0.50% |
| Total Impurities | ≤1.0% |
| Test Standard | Enterprise Standard |
| Usage | Ezetimibe (CAS: 163222-33-1) Intermediate |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4-[[(4-Fluorophenyl)imino]methyl]-phenol (CAS: 3382-63-6) with high quality, it is an intermediate typically in the synthesis of Ezetimibe (CAS: 163222-33-1).
Ezetimibe (CAS: 163222-33-1) is ananti-hyperlipidemic drug used for lowering the plasma cholesterol levels. Ezetimibe is a cholesterol transport inhibitor that binds to NPC1L1. It is indicated as an adjunctive therapy to diet for the reduction of high-level total-C, LDL-C, and ApoB in patients suffering primary (heterozygous familial and non-familial) hypercholesterolemia. It is also used in combination therapy with HMG-CoA reductase inhibitors.Ezetimibe does not inhibit the cholesterol synthesis in the liver, or increase bile acid excretion.It takes effect throughacting at the brush border of the small intestine and inhibiting the absorption of cholesterol, further leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of blood cholesterol.